Society for Immunotherapy of Cancer 2021 NEWS
Meet and greet: SITC 2021January 7, 2022 -- The Society for Immunotherapy of Cancer (SITC) 2021 meeting was an impactful event featuring the latest scientific and medical innovations in the field of immuno-oncology. These advances would not be possible if it were not for the dedicated professionals who work tirelessly to advance science's understanding of human health.
Battle royale: Self-cloaking virus vs. regenerating bacteriaJanuary 7, 2022 -- Which one is more likely to win in a fight: a self-cloaking virus or regenerating bacteria? These two groups of microbes can wreak havoc on the human body, albeit in vastly different ways. While there may be no right or wrong answer, ScienceBoard has initiated a long-term effort to probe experts on where they would place their bets in this epic fight.
5 takeaways from SITC 2021November 17, 2021 -- WASHINGTON, DC - The Society for Immunotherapy of Cancer's (SITC) 2021 annual meeting November 10-14 was a successful gathering of research and clinical experts focused on the development of innovative cancer treatments. The ScienceBoard team was live onsite at the event. Editor in Chief Samantha Black, PhD, shared five takeaways from the meeting.
Innovation and safety remain key amid shifting pandemic-impacted clinical trial protocolsNovember 16, 2021 -- WASHINGTON, DC - During the pandemic, clinical trial execution for cancer therapies has been challenging, said Dr. Samit Hirawat, chief medical officer at Bristol Myers Squibb, at the Society for Immunotherapy of Cancer's 2021 annual meeting. Despite the challenges presented by the pandemic, Hirawat noted that stakeholders held patient safety and innovation as key priorities. Hirawat spoke with ScienceBoard onsite at the meeting.
Where is the immunotherapy field headed after COVID-19?November 15, 2021 -- WASHINGTON, DC - Best known for his contributions to the Moderna COVID-19 vaccine, former Moderna chief medical officer, Dr. Tal Zaks, PhD, chaired a session on RNA vaccines at the Society for Immunotherapy of Cancer's (SITC) 2021 annual meeting. Zaks shared his perspectives and hopeful outlook with ScienceBoard at the meeting.
Is the accelerated approval process working for cancer immunotherapies?November 15, 2021 -- WASHINGTON, DC - Leveraging years of experience, Dr. Alessandra Cesano, PhD, who serves on the board of directors of the Society for Immunotherapy of Cancer (SITC), chaired a panel discussion on the accelerated approval process for cancer immunotherapies at the organization’s 2021 annual meeting. Cesano spoke with ScienceBoard at the meeting.
Researchers dig into how myeloid cells contribute to killing cancerNovember 15, 2021 -- WASHINGTON, DC - Dr. Miriam Merad, PhD, director of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai is working on characterizing myeloid cells in cancer patients. Merad spoke with ScienceBoard at the Society for Immunotherapy of Cancer's 2021 annual meeting.
New neoadjuvant platform helps inform combo immunotherapy selection for cancersNovember 13, 2021 -- WASHINGTON, DC - In order to address some of the major challenges facing the immuno-oncology field, Dr. Tom Marron, PhD, has developed a platform to help researchers decide which drugs or combination of drugs to advance toward late-stage clinical trials. Marron spoke with ScienceBoard Editor in Chief, Samantha Black, PhD, onsite at the Society for Immunotherapy of Cancer's 2021 annual meeting.
Society for Immunotherapy of Cancer 2021 Industry News